RhumbLine Advisers
BBNX

RhumbLine Advisers’s Beta Bionics BBNX Stock Holding History

RhumbLine Advisers’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$803K Buy
51,254
+4,824
+10% +$57.4K ﹤0.01% 2459
2026
Q1 		$465K Buy
46,430
+3,572
+8% +$52.8K ﹤0.01% 2657
2025
Q4 		$1.31M Sell
42,858
-4,259
-9% -$114K ﹤0.01% 2091
2025
Q3 		$936K Buy
47,117
+28,678
+156% +$504K ﹤0.01% 2285
2025
Q2 		$268K Buy
18,439
+5,559
+43% +$78.7K ﹤0.01% 3063
2025
Q1 		$158K Buy
+12,880
New +$240K ﹤0.01% 3222

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

RhumbLine Advisers's BBNX Position: Q2 2026 in Review

RhumbLine Advisers increased its Beta Bionics (BBNX) stake by 10% in Q2 2026, buying an estimated $57.4K and bringing the position to 51,254 shares worth $803K. The position accounts for ﹤0.01% of the portfolio, ranked #2459.

RhumbLine Advisers first reported a position in BBNX in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.31M in Q4 2025. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • RhumbLine Advisers held 51,254 shares of Beta Bionics worth $803K as of Q2 2026.
  • RhumbLine Advisers bought 4,824 Beta Bionics shares in Q2 2026, an estimated $57.4K.
  • Beta Bionics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2459 holding.
  • RhumbLine Advisers first reported a position in Beta Bionics in Q1 2025 and has held it in 6 quarters since.
  • RhumbLine Advisers's Beta Bionics position peaked at $1.31M in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.